Novo Nordisk is trading at DKK 306.05, up +4.24%, rebounding after recent selling tied to investor questions about Wegovy pill sales, pipeline prospects and the outlook despite raised guidance.
- No clear company-specific catalyst was identified for the August 7, 2026 move.
- Reuters reported shares fell as investors focused on disappointing Wegovy pill sales and a CagriSema trial setback.
- Trading activity and volume were unavailable in the supplied data.